Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Lepu Biopharma IPO: No Monetisation Timeline in Sight

Ping An Health (Part 1): A Deep Dive into Online Medical Services Business

Takeda: Excessive Reaction to Recent Setback in Trials; Drop in Share Price Offer Attractive Entry

M3: Strong 2Q Results but Earnings Growth Starts Decelerating

2022 High Conviction – Recruit: Post Covid Recovery May Be Short-Lived

Medlive IPO: Thoughts on First Day Trading

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Bottom-Up

<ul>
<li>Medlive is trading at HK$36.0 per share, 32.4% higher than the company’s IPO price of HK$27.2. The company’s shares have continued to trade at levels higher than its IPO price.</li>
<li>At FY2 EV/Revenue of 34.30x, Medlive appears attractive to us given the company is going through its high-growth phase alongside its proven business model and strong financials.</li>
<li>Medlive is well positioned to benefit from growing demand for digital healthcare in China which is at an early stage. </li>
</ul>


Medlive is trading at HK$36.0 per share, 32.4% higher than the company’s IPO price of HK$27.2. The company’s shares have continued to trade at levels higher than its IPO price.
At FY2 EV/Revenue of 34.30x, Medlive appears attractive to us given the company is going through its high-growth phase alongside its proven business model and strong financials.
Medlive is well positioned to benefit from growing demand for digital healthcare in China which is at an early stage. 


2022 High Conviction – Medlive: Key Beneficiary of Digital Healthcare Marketing in China

Medlive Technology

2022 High Conviction – Medlive: Key Beneficiary of Digital Healthcare Marketing in China